Argonaute RNA Ltd.

Based in the UK, Argonaute RNA Ltd. specializes in developing bispecific siRNA therapeutics that target and silence gene expressions linked to cardiometabolic diseases, addressing critical challenges in drug development. Founded in 2015 in Bristol, UK, Argonaute RNA Ltd. focuses on RNA-based therapeutics.

The company has conducted 2 deals, with the most recent funding round of GBP 1. 744 mn led by the Development Bank of Wales on April 25, 2024. CEO Michael Khan leads the firm, leveraging his extensive background in biotechnology. The company has not undergone significant changes in its strategic direction or ownership structure since its inception.

Argonaute RNA specializes in the development of bispecific siRNA therapeutics, designed to target and silence specific gene expressions implicated in cardiometabolic diseases. The company's core technology utilizes a proprietary modification of small interfering RNA (siRNA) that enhances the stability and safety of these therapeutics, addressing significant barriers previously encountered in siRNA drug development. The flagship product offerings include PULSE siRNA™ therapies, which offer a dual gene-silencing approach in a single molecule, catering to complex multi-factorial diseases where targeting multiple genes is crucial. Argonaute RNA primarily serves pharmaceutical partners and research institutions engaged in advanced therapeutic research, focusing on markets across North America and Europe where the demand for innovative cardiometabolic treatments is escalating.

Argonaute RNA's revenue model is anchored in partnerships with strategic pharmaceutical companies and innovation-driven investors, facilitating the development of its therapeutic offerings. These transactions typically involve collaboration agreements, where partners may fund research and development in exchange for potential future royalties or licensing rights to the developed siRNA therapeutics. Revenue is generated through these collaborative agreements, which may include milestone payments as specific development phases are achieved, along with potential sales from future products. The company’s focus on its PULSE siRNA™ platform positions it to engage in B2B transactions, appealing to larger pharmaceutical entities seeking solutions for unmet clinical needs in cardiometabolic health.

In July 2024, Argonaute RNA Ltd. raised GBP 1. 74 mn in venture funding led by the Development Bank of Wales, with participation from Bristol Private Equity Club, Fink Family Office, and Empirical Ventures. The company plans to use this funding to enhance the accessibility of its therapies for clinics and patients.

Future initiatives include launching new products targeting additional aspects of cardiometabolic health and expanding into North American and European markets by the end of 2025.